German biotech InflaRx raises $100M in IPO
InflaRx, a German biopharma developing drugs for rare diseases, has raised $100 million in the industry’s third IPO this month.
The company sold 6.7 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
